A PHASE-II TRIAL OF IFOSFAMIDE, 5-FLUOROURACIL, AND LEUCOVORIN IN RECURRENT UTERINE CERVICAL-CANCER

Thirty patients with recurrent squamous cell carcinoma of cervix uteri no longer amenable to control with surgery and/or radiotherapy were treated with a combination of ifosfamide, 5-fluorouracil, and Leucovorin every 4 weeks. The response rate was 53% (complete response, 33%; partial response, 20%). Response rates outside and inside irradiated area were 68 and 27%, respectively. The median progression-free interval was 7 months, and the median overall survival was 12 months. Adverse effects included primarily leukopenia, and dose reduction was necessary in 18 patients (60%). The present combination is active in the treatment of recurrent cervical cancer with a high response rate. The long-term survival is however still unsatisfactory. (C) 1994 Academic Press, Inc.